Search Results for "Rg7258 2012"
Matching Channels
Macitentan (Opsumit®) is a novel dual endothelin receptor antagonist (ERA) that resulted from a tailored drug discovery process with the target to develop an ERA optimized for efficacy and safet...
ATX-MS-1467 for patients with multiple sclerosis (MS)
ATX-MS-1467 is a novel treatment that was developed with the aim of working with the immune system to treat the underlying cause of disease rather than just treating the symptoms or suppressing the...
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain...
Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...
Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing p...
Matching News
RG7258: Development discontinued
Roche reports sales for new cancer drugs
Roche (SIX:ROG; OTCQX:RHHBY) reported 1H12 sales for its three newest cancer products, including CHF4 million ($4 million) in sales of Perjeta pertuzumab since its launch in June to treat previously u...
Singapore GDP grew more than expected in Q4
* Q4 GDP +3.3 pct q/q vs median forecast of +2.1 pct * Q4 GDP +1.5 pct y/y vs median forecast of +1.2 pct * Full-year 2012 GDP +1.3 percent * Singapore reiterates 2013 growth forecast of 1...
ALK-Abelló: Release date of nine-month interim report (Q3) 2012 for ALK
Copenhagen, 2012-10-29 16:13 CET (GLOBE NEWSWIRE) -- On Monday 12 November 2012, ALK releases its interim report for the nine months ended 30 September 2012. ALK will hold a conference call for ana...
Pfizer announces third-quarter 2012 dividend
The board of directors of Pfizer Inc. today declared a 22-cent third-quarter 2012 dividend on the company's common stock, payable September 5, 2012, to shareholders of record at the close of business...
November 7, 2012; Copenhagen, Denmark; Interim Report for the 9 Months Ended September 30, 2012 Company Announcement -- Entered global license and development agreement for daratumumab with Janssen...
2012 RPS award winners announced
Nine Royal Pharmaceutical Society awards for 2012 were presented at a ceremony held in Birmingham this evening (9 September 2012)
Patient Safety Technologies Reports Third Quarter 2012 Results
IRVINE, Calif., Nov. 5, 2012 /- Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced results for its third quarter of 2012 ended September 30 th , 2012. Expand...
Matching PubMed Articles
Nefrologia 2012;32(6):838-9. doi: 10.3265/Nefrologia.pre2012.Oct.11783. Reply to: Del Pozo et al. Comment on Nefrologia 2012;32(6):837. Nefrologia 2012; 32(4):419-26.
ISS/SIC Donations January 2012 Through June 2012.
Nefrologia 2012;32(6):835-7. doi: 10.3265/Nefrologia.pre2012.Oct.11731. Reply to: Serra Tarragon. Comment on Nefrologia 2012;32(6):835. Nefrologia 2012; 32(4):419-26.
Abstracts of the 2012 Vascular Annual Meeting. National Harbor, Maryland, USA. June 7-9, 2012.
